Source - RNS
RNS Number : 7694I
Clinigen Group plc
22 June 2017
 

22 June 2017

 

Issue of Equity

Clinigen Group plc (the "Group", AIM: CLIN) announces that it has made an application for the admission to trading on AIM of 1,676 ordinary shares of 0.1 pence each in the Group (the "New Ordinary Shares"), which have been issued to satisfy the exercise of share options and rank pari passu with the existing shares of the Group. Admission to trading on AIM of the New Ordinary Shares is anticipated to occur on 27 June 2017.

 

At admission the issued share capital of the Group will consist of 115,154,117 ordinary shares, with no shares held in treasury. The total number of voting rights in the Group will therefore be 115,154,117. This figure may be used by shareholders as the denominator to determine if they are required to notify their interests in, or a change to their interest in, the Group under the Disclosure Guidance and Transparency Rules.

 

 

-Ends-

 

Contact details

 

Clinigen Group plc

Tel: +44 (0) 1283 495010

Shaun Chilton, Group Chief Executive Officer


Martin Abell, Group Chief Financial Officer




Numis Securities Limited

Tel: +44 (0) 20 7260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)

James Black / Tom Ballard  (Corporate Broking)




RBC Capital Markets - Joint Broker

Tel: +44 (0) 20 7653 4000

Marcus Jackson / Elliot Thomas / Jack Wood




Instinctif Partners

Tel: +44 (0) 20 7457 2020

Adrian Duffield / Melanie Toyne-Sewell / Alex Shaw

Email: [email protected]

 

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing access to medicines. Its mission is to deliver the right medicine to the right patient at the right time.

 

The Group consists of five synergistic businesses focused in three areas of global medicine supply; clinical trial, unlicensed and licensed medicines.

 

Clinigen Clinical Trial Services is the global market leader in the management and supply of commercial medicines for clinical trials.

 

The Group is also the trusted global leader in ethically sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet need, through three of its divisions: Idis Managed Access runs early access programmes for innovative new medicines. Idis Global Access and Link Healthcare work directly with healthcare professionals to enable compliant access to unlicensed medicines on a global basis and niche essential licensed and generic medicines across Australasia, Africa and Asia (AAA region).

 

Clinigen Specialty Pharmaceuticals acquires global rights, revitalises and markets its own portfolio of niche hospital products.

 

For more information, please visit www.clinigengroup.com 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOESEFFFFFWSEDM